ACCREDITATION The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation. The Endocrine Society designates this educational activity for a maximum of 2.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. STATEMENT OF INDEPENDENCE As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of The Endocrine Society's Special Programs Committee (SPC). The commercial supporters of this activity have no influence over the selection of the faculty or specific presentations. DISCLAIMER The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society. LEARNING OBJECTIVES Upon completion of this educational activity, learners will be able to: Discuss the relative merits of approaches to determining individualized fracture risk. Identify current advances and controversies in antiresorptive therapy and their impact on clinical care. Evaluate the role of RANK-L in bone metabolism and osteoporosis therapy. TARGET AUDIENCE This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows and healthcare professionals who treat patients with osteoporosis. DISCLOSURE POLICY The faculty, committee members, and staff involved in planning this CME activity are required to disclose to learners any relevant financial relationship(s) that have occurred within the last 12 months with any commercial interest(s) whose products or services are discussed in the CME content. Such relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent faculty or others with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments. It remains for learners to determine whether financial interests or relationships may influence the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable. The following faculty reported relevant financial relationships: John P. Bilezikian, MD, has received consulting fees from Eli Lilly, Novartis, Alliance for Better Bone Health, NPS Pharmaceuticals, Merck and Amgen and speaker fees from Eli Lilly, Novartis, and the Alliance for Better Bone Health. Dolores M. Shoback, MD, has received consulting fees from Amgen and speaker honoraria from Novartis. Michael R. McClung, MD, has received consulting fees and research support from Amgen, Lilly, Merck, Novartis, Proctor & Gamble, sanofi-aventis, and Takeda. The following faculty reported no relevant financial relationships: Dennis M. Black, PhD The following [committee] members who planned and/or reviewed content for this activity reported relevant financial relationships: Deborah Sellmeyer, MD, has received research funds for her role as DSMB member for Novartis and clinical trial site investigator for Amgen. Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships. POLICY ON UNLABELED/OFF-LABEL USAGE The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial products is informative for audiences and therefore requires that speakers disclose this information to the learners at the beginning of the presentations. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such "off-label" use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events. PRIVACY & CONFIDENTIALITY STATEMENT The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties. ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT This activity was supported by an educational grant from Amgen. METHOD OF PARTICIPATION This enduring material is presented in an online/computer-based format. System requirements include: For Windows, Firefox 1.5 or Internet Explorer 6.0 with Flash 8 or better installed. For Macintosh OS X, Safari 2.0 or Firefox 1.5 with Flash 8 or better installed. To receive AMA PRA Category 1 Credits™, the learner should: Listen to the audio and/or view the slides. Complete the evaluation provided at the end of the activity and click on "submit" to add it to the learner's transcript. The transcript will appear and the learner will have the option of printing a CME certificate then or at a later time, after viewing other CME offerings. Estimated time to complete this activity: 2.50 hours Last Review Date: June 30, 2010 RELEASE DATE: June 30, 2010 TERMINATION DATE: June 30, 2011 For technical assistance or information, please contact Content Management Corporation at 1-888-711-1138 ext.241 or 972-910-6899 (9:00 AM to 5:00 PM EST or multiviewMediaSupport@multiview.com. For questions regarding CME content or obtaining CME credit, please contact The Endocrine Society at 301.941.0200 or education@endo-society.org.

I have read the CME guidelines outlined.